CA2937243C - Modified release formulations of pridopidine - Google Patents
Modified release formulations of pridopidine Download PDFInfo
- Publication number
- CA2937243C CA2937243C CA2937243A CA2937243A CA2937243C CA 2937243 C CA2937243 C CA 2937243C CA 2937243 A CA2937243 A CA 2937243A CA 2937243 A CA2937243 A CA 2937243A CA 2937243 C CA2937243 C CA 2937243C
- Authority
- CA
- Canada
- Prior art keywords
- pridopidine
- solid oral
- dosage form
- oral dosage
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Inorganic Chemistry (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Botany (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Oil, Petroleum & Natural Gas (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461930358P | 2014-01-22 | 2014-01-22 | |
| US61/930,358 | 2014-01-22 | ||
| US201462050626P | 2014-09-15 | 2014-09-15 | |
| US62/050,626 | 2014-09-15 | ||
| PCT/US2015/012248 WO2015112601A1 (en) | 2014-01-22 | 2015-01-21 | Modified release formulations of pridopidine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2937243A1 CA2937243A1 (en) | 2015-07-30 |
| CA2937243C true CA2937243C (en) | 2023-07-18 |
Family
ID=53543863
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2937243A Active CA2937243C (en) | 2014-01-22 | 2015-01-21 | Modified release formulations of pridopidine |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US20150202302A1 (https=) |
| EP (2) | EP4049657A1 (https=) |
| JP (2) | JP6949487B2 (https=) |
| KR (1) | KR102479759B1 (https=) |
| CN (1) | CN106170287A (https=) |
| AU (1) | AU2015209411A1 (https=) |
| CA (1) | CA2937243C (https=) |
| CL (1) | CL2016001874A1 (https=) |
| DK (1) | DK3096759T3 (https=) |
| EA (1) | EA201691454A1 (https=) |
| ES (1) | ES2911800T3 (https=) |
| HU (1) | HUE058288T2 (https=) |
| IL (2) | IL246598B (https=) |
| MX (1) | MX377576B (https=) |
| PE (1) | PE20161220A1 (https=) |
| PL (1) | PL3096759T3 (https=) |
| TW (1) | TW201605446A (https=) |
| UA (1) | UA122053C2 (https=) |
| UY (1) | UY35962A (https=) |
| WO (1) | WO2015112601A1 (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
| JP2013536825A (ja) | 2010-09-03 | 2013-09-26 | イバックス・インターナショナル・ゲーエムベーハー | ドパミン作動性安定化剤として有用なプリドピジンの重水素化類似体 |
| TWI579272B (zh) | 2011-12-08 | 2017-04-21 | 梯瓦製藥國際有限責任公司 | 普多比啶（ｐｒｉｄｏｐｉｄｉｎｅ）之氫溴酸鹽 |
| US11090297B2 (en) | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
| HK1221646A1 (zh) | 2013-06-21 | 2017-06-09 | Teva Pharmaceuticals International Gmbh | 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途 |
| MX377576B (es) | 2014-01-22 | 2025-03-04 | Prilenia Neurotherapeutics Ltd | Formulaciones de pridopidina de liberación modificada. |
| TW201613859A (en) | 2014-06-30 | 2016-04-16 | Teva Pharma | Analogs of PRIDOPIDINE, their preparation and use |
| MX2017008136A (es) | 2014-12-22 | 2018-03-06 | Teva Pharmaceuticals Int Gmbh | Sal de l-tartrato de pridopidina. |
| JP6887952B2 (ja) | 2015-02-25 | 2021-06-16 | プリレニア ニューロセラピューティクス リミテッド | 認知機能を改善するため、およびアルツハイマー病を治療するためのプリドピジンの使用 |
| US11471449B2 (en) | 2015-02-25 | 2022-10-18 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to improve cognitive function and for treating Alzheimer's disease |
| EP3324967A4 (en) * | 2015-07-22 | 2019-03-20 | Prilenia Therapeutics Development Ltd. | PRIDOPIDINE-BASED FORMULATIONS AND USE OF THE SAME |
| AR105434A1 (es) | 2015-07-22 | 2017-10-04 | Teva Pharmaceuticals Int Gmbh | Proceso para preparar pridopidina |
| JP7034488B2 (ja) * | 2016-02-24 | 2022-03-14 | プリレニア・ニューロセラピューティクス・エルティーディー | プリドピジンを使用する神経変性眼疾患の治療 |
| EP4516356A3 (en) | 2016-08-24 | 2025-05-14 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for treating functional decline |
| CA3035099C (en) * | 2016-08-24 | 2023-01-17 | Prilenia Therapeutics Development Ltd. | Use of pridopidine for treating dystonias |
| HUE058314T2 (hu) * | 2016-09-16 | 2022-07-28 | Prilenia Neurotherapeutics Ltd | Pridopidin alkalmazása Rett-szindróma kezelésére |
| US12102627B2 (en) * | 2016-09-16 | 2024-10-01 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for treating rett syndrome |
| CA3050700C (en) | 2017-01-20 | 2023-10-03 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for the treatment of fragile x syndrome |
| SI4154882T1 (sl) | 2017-08-14 | 2026-01-30 | Prilenia Neurotherapeutics Ltd. | Zdravljenje amiotrofične lateralne skleroze s pridopidinom |
| CA3073568A1 (en) * | 2017-08-30 | 2019-03-07 | Prilenia Neurotherapeutics Ltd. | High concentration dosage forms of pridopidine |
| JP2020533296A (ja) | 2017-09-08 | 2020-11-19 | プリレニア ニューロセラピューティクス リミテッド | 薬物誘発性ジスキネジアを治療するためのプリドピジン |
| US12036213B2 (en) | 2017-09-08 | 2024-07-16 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating drug induced dyskinesias |
| KR20200056071A (ko) | 2018-11-14 | 2020-05-22 | 한화토탈 주식회사 | 내열성, 강성 및 용융 강도가 우수한 폴리올레핀 수지 조성물 |
| CN113395964A (zh) * | 2019-02-04 | 2021-09-14 | 普瑞尼亚神经治疗有限公司 | 用于帕金森氏病和与帕金森症相关的其它疾病的低剂量普利多匹定 |
| CN116472043A (zh) * | 2020-10-20 | 2023-07-21 | 普瑞尼亚神经治疗有限公司 | 普利多匹定和类似物用于治疗焦虑和抑郁的用途 |
| WO2024258929A1 (en) * | 2023-06-12 | 2024-12-19 | Unravel Biosciences, Inc. | Methods for treating diseases associated with taf1 loss of function |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4020983B2 (ja) * | 1995-07-07 | 2007-12-12 | 帝國製薬株式会社 | 持続性製剤およびその製法 |
| SE9904724D0 (sv) | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission I |
| CA2403380A1 (en) * | 2000-03-21 | 2002-09-19 | Nippon Shinyaku Co., Ltd. | Sustained release oral preparations |
| AR030557A1 (es) * | 2000-04-14 | 2003-08-27 | Jagotec Ag | Una tableta en multicapa de liberacion controlada y metodo de tratamiento |
| GB0125088D0 (en) * | 2001-10-18 | 2001-12-12 | Smithkline Beecham Cork Ltd | New use |
| MXPA06002455A (es) * | 2003-09-02 | 2006-08-31 | Pfizer Prod Inc | Formas de dosificacion de liberacion sostenida de ziprasidona. |
| CA2584831C (en) | 2004-10-13 | 2013-09-17 | Neurosearch Sweden Ab | Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-n-propyl-piperidine |
| US20110206782A1 (en) * | 2010-02-24 | 2011-08-25 | Auspex Pharmaceuticals, Inc. | Piperidine modulators of dopamine receptor |
| TWI579272B (zh) * | 2011-12-08 | 2017-04-21 | 梯瓦製藥國際有限責任公司 | 普多比啶（ｐｒｉｄｏｐｉｄｉｎｅ）之氫溴酸鹽 |
| AU2013243461A1 (en) | 2012-04-04 | 2014-11-06 | Teva Pharmaceuticals International Gmbh | Pharmaceutical compositions for combination therapy |
| HK1221646A1 (zh) * | 2013-06-21 | 2017-06-09 | Teva Pharmaceuticals International Gmbh | 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途 |
| MX377576B (es) | 2014-01-22 | 2025-03-04 | Prilenia Neurotherapeutics Ltd | Formulaciones de pridopidina de liberación modificada. |
-
2015
- 2015-01-21 MX MX2016009427A patent/MX377576B/es active IP Right Grant
- 2015-01-21 JP JP2016547847A patent/JP6949487B2/ja active Active
- 2015-01-21 WO PCT/US2015/012248 patent/WO2015112601A1/en not_active Ceased
- 2015-01-21 EA EA201691454A patent/EA201691454A1/ru unknown
- 2015-01-21 PE PE2016001263A patent/PE20161220A1/es not_active Application Discontinuation
- 2015-01-21 EP EP22163271.4A patent/EP4049657A1/en not_active Withdrawn
- 2015-01-21 UA UAA201608936A patent/UA122053C2/uk unknown
- 2015-01-21 EP EP15740303.1A patent/EP3096759B1/en active Active
- 2015-01-21 DK DK15740303.1T patent/DK3096759T3/da active
- 2015-01-21 AU AU2015209411A patent/AU2015209411A1/en not_active Abandoned
- 2015-01-21 US US14/601,920 patent/US20150202302A1/en not_active Abandoned
- 2015-01-21 PL PL15740303T patent/PL3096759T3/pl unknown
- 2015-01-21 CN CN201580005659.9A patent/CN106170287A/zh active Pending
- 2015-01-21 KR KR1020167022884A patent/KR102479759B1/ko active Active
- 2015-01-21 CA CA2937243A patent/CA2937243C/en active Active
- 2015-01-21 HU HUE15740303A patent/HUE058288T2/hu unknown
- 2015-01-21 ES ES15740303T patent/ES2911800T3/es active Active
- 2015-01-22 TW TW104102153A patent/TW201605446A/zh unknown
- 2015-01-22 UY UY0001035962A patent/UY35962A/es not_active Application Discontinuation
-
2016
- 2016-07-04 IL IL246598A patent/IL246598B/en active IP Right Grant
- 2016-07-22 CL CL2016001874A patent/CL2016001874A1/es unknown
-
2018
- 2018-08-28 US US16/115,105 patent/US20190209542A1/en not_active Abandoned
-
2019
- 2019-09-30 JP JP2019179329A patent/JP7266298B2/ja active Active
-
2021
- 2021-01-28 IL IL280485A patent/IL280485B2/en unknown
-
2023
- 2023-10-23 US US18/491,871 patent/US20240041855A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240041855A1 (en) | Modified release formulations of pridopidine | |
| US20170020854A1 (en) | Pridopidine base formulations and their use | |
| BR112012028035B1 (pt) | formulação de liberação imediata | |
| CN102387802A (zh) | 包含羟考酮和纳洛酮的立即释放药物组合物 | |
| WO2008070072A2 (en) | Carvedilol forms, compositions, and methods of preparation thereof | |
| JP2009542647A (ja) | メマンチン医薬組成物 | |
| CN104840443B (zh) | 含活性成分普瑞巴林的药物组合物 | |
| CN112804998A (zh) | Ag10的制剂 | |
| Tayel et al. | Comparative study between different ready-made orally disintegrating platforms for the formulation of sumatriptan succinate sublingual tablets | |
| EP2397122B1 (en) | Formulations of neramexane dosage forms | |
| WO2021197451A1 (zh) | 一种替格瑞洛的多元制剂 | |
| HK40077943A (en) | Modified release formulations of pridopidine | |
| JP6328138B2 (ja) | Ｎ−［５−［２−（３，５−ジメトキシフェニル）エチル］−２ｈ−ピラゾール−３−イル］−４−［（３ｒ，５ｓ）−３，５−ジメチルピペラジン−１−イル］ベンズアミドの医薬製剤 | |
| US20220249479A1 (en) | Modified release formulation of a pyrimidinylamino-pyrazole compound, and methods of treatment | |
| Siraj et al. | Formulation development and evaluation of highly water-soluble drug-loaded controlled release matrix tablets | |
| CN108066297B (zh) | 治疗老年痴呆症的定位释放美金刚口腔崩解片组合物 | |
| HK1226651A1 (en) | Modified release formulations of pridopidine | |
| EA040574B1 (ru) | Твердая пероральная лекарственная форма модифицированного высвобождения, содержащая придопидин | |
| PACKIARAJ | FORMULATION AND EVALUATION OF CONTROLLED-RELEASE DOSAGE FORM OF CLARITHROMYCIN & PREDNISONE AS MODEL DRUGS | |
| Reddy | Formulation And Evaluation Of Sustained Release Matrix Tablet Of An Anti-Hypertensive Drug |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20191004 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD Year of fee payment: 10 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241127 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241127 Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241127 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD Year of fee payment: 11 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251202 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251202 |